放射性配體治療的全球市場

預計到 2030 年，全球放射性配體治療市場規模將達到 120 億美元

全球放射性配體治療市場規模預計在2024年為100億美元，預計2030年將達到120億美元，2024年至2030年的複合年成長率為3.0%。前列腺癌是本報告分析的細分市場之一，預計其複合年成長率為2.5%，到分析期結束時將達到51億美元。神經內分泌腫瘤細分市場在分析期間的複合年成長率預計為2.5%。

美國市場規模估計為 27 億美元，中國市場預計複合年成長率為 5.6%

美國放射性配體治療市場規模預計2024年達到27億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到23億美元，在2024-2030年的分析期間內，複合年成長率為5.6%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為1.2%和2.3%。在歐洲，預計德國市場的複合年成長率為1.7%。

全球「放射性配體療法」市場—主要趨勢與促進因素摘要

放射性配體療法會重新定義癌症治療模式嗎？

放射性配體療法 (RLT) 是一種標靶、微創的傳統癌症治療方法，被公認為癌症治療的突破性方法。 RLT 將放射性同位素附著在特異性針對癌細胞的配體上，將放射線直接輸送到癌症組織，同時不傷害健康組織。這種機制可產生精確的細胞毒性，同時減少全身性副作用，使 RLT 成為轉移性癌症和抗治療性癌症的突破性治療方法。核准的治療方法，如 Lutathera（用於治療神經內分泌腫瘤）和 Pluvicto（用於治療轉移性前列腺癌），已顯示出可顯著提高生存率和生活品質。對腫瘤生物標記和受體譜的深入了解使得開發針對更廣泛惡性腫瘤的新型放射性配體成為可能。隨著精準醫療成為臨床當務之急，放射性配體療法正從小眾選擇發展成為晚期癌症治療方法的核心組成部分。

同位素和配體開發方面的創新如何擴展 RLT 的能力？

放射性藥物工程的進展正在迅速提高放射性配體治療的安全性、有效性和治療範圍。螯合劑化學的創新正在提高鎦-177、錒-225和釔-90等同位素的穩定性和結合親和性。胜肽和抗體工程的進展也同步推進，提高了腫瘤選擇性並延長了循環半衰期。研究人員目前正在開發可用於影像和治療的雙標靶配體和診療偶聯物，從而促進即時治療監測和劑量最佳化。新型放射性核種也被引入，以克服穿透深度和照射範圍的局限性，使放射性核種治療（RLT）對小型腫瘤和深部腫瘤均有效。這些創新有助於擴大放射性核種在先前無法治癒的癌症中的應用，並改善抗藥性腫瘤的治療效果。不斷發展的同位素和配體套件包為RLT的更廣泛應用和個性化奠定了基礎。

臨床基礎設施和報銷政策是否能夠滿足日益成長的 RLT 需求？

雖然放射性配體療法的臨床價值顯而易見，但其推廣在基礎設施準備和監管途徑方面仍面臨挑戰。放射性配體療法 (RLT) 需要專門的設施來生產、安全處理和為患者提供治療。同位素（尤其是α發射核素）的取得管道有限，導致許多地區出現供應鏈瓶頸。此外，將 RLT 整合到腫瘤學工作流程中需要核子醫學、放射科和腫瘤科之間的協作，從而需要跨學科培訓和方案製定。保險報銷也仍然不一致，覆蓋範圍通常僅限於核准的適應症和特定地區。然而，全球衛生當局越來越認知到 RLT 在晚期癌症中的成本效益，從而增加了資金投入和政策支持。官民合作關係有助於擴大同位素供應和治療基礎設施。隨著認知度的提高和監管協調的改善，物流障礙有望減少，RLT 的可及性也將擴大。

是什麼推動了放射性配體治療市場的加速成長？

放射性配體治療市場的成長受到多種因素的驅動，這些因素源自於技術發展、腫瘤學需求和不斷發展的醫療保健政策。從技術上講，更穩定的同位素、最佳化的配體和治療診斷模型的出現正在提高臨床成功率並擴大應用範圍。就最終用途趨勢而言，晚期和抗藥性癌症的發生率正在上升，而 RLT 對此帶來了新的希望。製藥公司正在積極投資 RLT 管道，核醫學領域的併購正在推動創新。醫療保健系統越來越重視個人化、基於價值的護理，使 RLT 成為一種策略一致的選擇。患者對微創、高效治療的需求進一步加速了市場採用。全球監管機構也在簡化核准途徑，透過快速通道指定和資金獎勵鼓勵新開發。這些因素共同使 RLT 成為主流癌症治療方法。

部分

適應症（前列腺癌、神經內分泌腫瘤、乳癌、其他適應症）；同位素（氟-18、鎵-68、鎦-177、其他同位素）；最終用戶（醫院和診所、診斷中心、其他最終用戶）

受訪公司範例（總合42家公司）

• Accuray Incorporated
• Advanced Accelerator Applications
• ARTBIO
• AstraZeneca
• Bayer AG
• Curium Pharma
• Eli Lilly and Company
• Endocyte Inc.
• Fusion Pharmaceuticals
• ITM Isotope Technologies Munich SE
• Johnson & Johnson Services Inc.
• Lantheus Holdings, Inc.
• Molecular Partners AG
• Nanobiotix
• Novartis AG
• Orano Med
• Pfizer Inc.
• POINT Biopharma Global Inc.
• Precirix NV
• Telix Pharmaceuticals Limited

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口（成品和原始OEM）來預測其競爭地位的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括人為提高銷貨成本、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

全球產業分析師密切關注來自全球頂尖首席經濟學家（14,949位）、智庫（62家）以及貿易和產業協會（171家）的專家的意見，以評估其對生態系統的影響並應對新的市場現實。我們追蹤了來自每個主要國家的專家和經濟學家對關稅及其對本國影響的看法。

全球產業分析師預計，這場動盪將在未來2-3個月內逐漸平息，新的世界秩序將更加清晰地建立。全球產業分析師正在即時追蹤這些事態發展。

2025年4月：談判階段

在4月的報告中，我們將探討關稅對全球整體市場的影響，並提供區域市場調整。我們的預測是基於歷史數據和不斷變化的市場影響因素。

2025年7月：最終關稅調整

在各國宣布最終重置後，客戶將在 7 月收到免費更新，最終更新將包含明確的關稅影響分析。

相互和雙邊貿易及關稅影響分析：

美國<>中國<>墨西哥<>加拿大<>歐盟<>日本<>印度<>其他176個國家

領先的產業經濟學家：全球產業分析師知識庫追蹤了 14,949 位經濟學家，其中包括來自民族國家、智庫、貿易和產業協會、大型企業以及各領域專家的最具影響力的首席經濟學家，他們共用了這場前所未有的全球經濟狀況模式轉移的影響。我們超過 16,491 份報告大多遵循基於里程碑的兩階段發布計劃。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 澳洲
• 印度
• 韓國
• 其他亞太地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 競賽

Global Radioligand Therapy Market to Reach US$12.0 Billion by 2030

The global market for Radioligand Therapy estimated at US$10.0 Billion in the year 2024, is expected to reach US$12.0 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Prostate Cancer Indication, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Neuroendocrine Tumors Indication segment is estimated at 2.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 5.6% CAGR

The Radioligand Therapy market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 5.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global "Radioligand Therapy" Market - Key Trends & Drivers Summarized

Is Radioligand Therapy Redefining Cancer Treatment Paradigms?

Radioligand therapy (RLT) is gaining recognition as a breakthrough approach in oncology, offering a targeted and minimally invasive alternative to conventional cancer therapies. By binding radioactive isotopes to ligands that specifically target tumor cells, RLT delivers radiation directly to cancerous tissues while sparing healthy ones. This mechanism provides precise cytotoxicity with fewer systemic side effects, positioning RLT as a game-changer in treating metastatic and treatment-resistant cancers. Approved therapies like Lutathera (for neuroendocrine tumors) and Pluvicto (for metastatic prostate cancer) have demonstrated significant survival benefits and quality-of-life improvements. The growing understanding of tumor biomarkers and receptor profiles is enabling the development of new radioligands targeting a wider range of malignancies. As precision medicine becomes a clinical imperative, radioligand therapy is transitioning from a niche option to a core component of advanced oncology regimens.

How Are Innovations in Isotope and Ligand Development Expanding RLT Potential?

Advances in radiopharmaceutical engineering are rapidly enhancing the safety, efficacy, and reach of radioligand therapies. Innovations in chelator chemistry are improving the stability and binding affinity of isotopes like Lutetium-177, Actinium-225, and Yttrium-90. Parallel progress in peptide and antibody engineering is allowing for better tumor selectivity and longer circulatory half-lives. Researchers are now developing dual-targeting ligands and theranostic pairs that can be used for both imaging and therapy, facilitating real-time treatment monitoring and dose optimization. New radionuclides are also being introduced to overcome limitations of penetration depth and radiation range, making RLT effective for both small and deep-seated tumors. These innovations are helping to expand radioligand applications to previously untreatable cancers and improving outcomes in resistant tumor profiles. The evolving toolkit of isotopes and ligands is setting the stage for broader RLT adoption and personalization.

Can Clinical Infrastructure and Reimbursement Policies Keep Pace With Growing RLT Demand?

While radioligand therapy's clinical value is clear, its expansion is challenged by infrastructure readiness and regulatory pathways. RLT requires specialized facilities for radiopharmaceutical production, safe handling, and patient administration. Limited access to isotopes, especially alpha emitters, remains a supply chain hurdle in many regions. Moreover, the integration of RLT into oncology workflows demands collaboration between nuclear medicine, radiology, and oncology departments, necessitating cross-disciplinary training and protocol development. Reimbursement also remains inconsistent, with coverage often limited to approved indications or specific geographic regions. However, global health authorities are increasingly recognizing the cost-effectiveness of RLT in advanced cancer stages, leading to improved funding and policy support. Public-private partnerships are helping expand isotope supply and treatment infrastructure. As awareness grows and regulatory harmonization improves, logistical barriers are expected to diminish, unlocking wider RLT access.

What’s Powering The Radioligand Therapy Market’s Accelerated Growth?

The growth in the radioligand therapy market is driven by several factors rooted in technological development, oncological needs, and healthcare policy evolution. Technologically, the emergence of more stable isotopes, optimized ligands, and theranostic models is increasing clinical success rates and broadening applications. End-use trends highlight a rising incidence of late-stage and resistant cancers, where RLT offers a new line of hope. Pharmaceutical companies are aggressively investing in RLT pipelines, and M&A activity in the nuclear medicine space is fostering innovation. Healthcare systems are increasingly prioritizing personalized and value-based care, making RLT a strategically aligned option. Patient demand for minimally invasive, high-efficacy treatments is further accelerating market uptake. Global regulatory bodies are also streamlining approval pathways, with fast-track designations and funding incentives bolstering new development. Together, these factors are propelling RLT into the mainstream of cancer care.

SCOPE OF STUDY:

The report analyzes the Radioligand Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Prostate Cancer, Neuroendocrine Tumors, Breast Cancer, Other Indications); Isotope (Fluorine-18, Gallium-68, Lutetium-177, Other Isotopes); End-Use (Hospitals & Clinics, Diagnostic Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Accuray Incorporated
• Advanced Accelerator Applications
• ARTBIO
• AstraZeneca
• Bayer AG
• Curium Pharma
• Eli Lilly and Company
• Endocyte Inc.
• Fusion Pharmaceuticals
• ITM Isotope Technologies Munich SE
• Johnson & Johnson Services Inc.
• Lantheus Holdings, Inc.
• Molecular Partners AG
• Nanobiotix
• Novartis AG
• Orano Med
• Pfizer Inc.
• POINT Biopharma Global Inc.
• Precirix NV
• Telix Pharmaceuticals Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Radioligand Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Targeted Cancers Propels Demand for Radioligand Therapy Solutions
  • Expansion of Theranostics Enhances the Appeal of Dual Diagnostic and Treatment Approaches
  • Increased FDA and EMA Approvals for Radioligand-Based Therapies Accelerate Market Entry
  • Strong Pipeline of Oncology-Focused Radiopharmaceuticals Sustains Long-Term Growth
  • Partnerships Between Pharma Giants and Nuclear Medicine Innovators Strengthen Commercialization
  • Breakthroughs in Ligand Development and Target Specificity Improve Clinical Outcomes
  • Growing Integration in Advanced Prostate and Neuroendocrine Tumor Treatment Protocols Drives Adoption
  • Radioligand Therapy's Lower Side Effect Profile Strengthens Its Role in Precision Medicine
  • Manufacturing and Distribution Challenges for Radioisotopes Create Supply Bottlenecks
  • Rising Investment in Radiopharmaceutical CDMOs Expands Production Capacity and Market Reach
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Radioligand Therapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Radioligand Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Radioligand Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Radioligand Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Neuroendocrine Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Neuroendocrine Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Neuroendocrine Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Fluorine-18 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Fluorine-18 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Fluorine-18 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Gallium-68 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Gallium-68 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Gallium-68 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Lutetium-177 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Lutetium-177 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Lutetium-177 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Other Isotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Other Isotopes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Other Isotopes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• JAPAN
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• CHINA
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 65: China Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 68: China Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: China Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: China 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 71: China Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• EUROPE
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Radioligand Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Radioligand Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Radioligand Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 80: Europe Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Europe Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Europe 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• FRANCE
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 86: France Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 89: France Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: France Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: France 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 92: France Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: France Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: France 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• GERMANY
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 98: Germany Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Germany Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Germany 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 101: Germany Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Germany Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Germany 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 107: Italy Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Italy Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Italy 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 110: Italy Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Italy Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Italy 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 113: UK Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 116: UK Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: UK Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: UK 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 119: UK Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: UK Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: UK 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 125: Spain Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Spain Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Spain 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 128: Spain Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Spain Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Spain 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 134: Russia Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Russia Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Russia 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 137: Russia Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Russia Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Russia 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Rest of Europe Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Rest of Europe 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Rest of Europe Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Rest of Europe 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Radioligand Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Radioligand Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Radioligand Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Asia-Pacific Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Asia-Pacific 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Asia-Pacific Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Asia-Pacific 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 164: Australia Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Australia Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Australia 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 167: Australia Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Australia Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Australia 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• INDIA
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 170: India Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 173: India Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: India Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: India 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 176: India Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: India Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: India 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 182: South Korea Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: South Korea Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: South Korea 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 185: South Korea Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: South Korea Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: South Korea 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Asia-Pacific Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Asia-Pacific Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Radioligand Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Radioligand Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Radioligand Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 203: Latin America Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Latin America Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Latin America 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 206: Latin America Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Latin America Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Latin America 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 212: Argentina Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Argentina Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Argentina 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 215: Argentina Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Argentina Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Argentina 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 221: Brazil Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Brazil Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Brazil 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 224: Brazil Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Brazil Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Brazil 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 230: Mexico Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Mexico Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Mexico 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 233: Mexico Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Mexico Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Mexico 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Latin America Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Latin America 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Latin America Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Latin America 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Radioligand Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Radioligand Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Radioligand Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 251: Middle East Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Middle East Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Middle East 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 254: Middle East Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Middle East Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Middle East 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 260: Iran Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Iran Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Iran 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 263: Iran Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Iran Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Iran 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 269: Israel Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Israel Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Israel 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 272: Israel Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Israel Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Israel 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Saudi Arabia Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Saudi Arabia 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Saudi Arabia Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Saudi Arabia 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 287: UAE Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: UAE Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: UAE 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 290: UAE Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: UAE Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: UAE 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Middle East Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Middle East 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Middle East Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Middle East 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030
• AFRICA
  • Radioligand Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Radioligand Therapy by Indication - Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Radioligand Therapy by Indication - Percentage Breakdown of Value Sales for Prostate Cancer, Neuroendocrine Tumors, Breast Cancer and Other Indications for the Years 2015, 2025 & 2030
  • TABLE 305: Africa Recent Past, Current & Future Analysis for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Africa Historic Review for Radioligand Therapy by End-Use - Diagnostic Centers, Other End-Uses and Hospitals & Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Africa 15-Year Perspective for Radioligand Therapy by End-Use - Percentage Breakdown of Value Sales for Diagnostic Centers, Other End-Uses and Hospitals & Clinics for the Years 2015, 2025 & 2030
  • TABLE 308: Africa Recent Past, Current & Future Analysis for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Africa Historic Review for Radioligand Therapy by Isotope - Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Africa 15-Year Perspective for Radioligand Therapy by Isotope - Percentage Breakdown of Value Sales for Fluorine-18, Gallium-68, Lutetium-177 and Other Isotopes for the Years 2015, 2025 & 2030

IV. COMPETITION